These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 15003649)
21. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252 [TBL] [Abstract][Full Text] [Related]
23. DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice. Rasmussen RA; Ong H; Kittel C; Ruprecht CR; Ferrantelli F; Hu SL; Polacino P; McKenna J; Moon J; Travis B; Ruprecht RM Vaccine; 2006 Mar; 24(13):2324-32. PubMed ID: 16406147 [TBL] [Abstract][Full Text] [Related]
24. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757 [TBL] [Abstract][Full Text] [Related]
25. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost. Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074 [TBL] [Abstract][Full Text] [Related]
26. The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope. Benferhat R; Martinon F; Krust B; Le Grand R; Hovanessian AG Mol Immunol; 2009 Feb; 46(4):705-12. PubMed ID: 19010547 [TBL] [Abstract][Full Text] [Related]
27. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Cristillo AD; Lisziewicz J; He L; Lori F; Galmin L; Trocio JN; Unangst T; Whitman L; Hudacik L; Bakare N; Whitney S; Restrepo S; Suschak J; Ferrari MG; Chung HK; Kalyanaraman VS; Markham P; Pal R Virology; 2007 Sep; 366(1):197-211. PubMed ID: 17499328 [TBL] [Abstract][Full Text] [Related]
28. Helminth infection suppresses T-cell immune response to HIV-DNA-based vaccine in mice. Da'Dara AA; Lautsch N; Dudek T; Novitsky V; Lee TH; Essex M; Harn DA Vaccine; 2006 Jun; 24(24):5211-9. PubMed ID: 16675073 [TBL] [Abstract][Full Text] [Related]
29. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639 [TBL] [Abstract][Full Text] [Related]
30. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Buckner C; Gines LG; Saunders CJ; Vojtech L; Srivastava I; Gettie A; Bohm R; Blanchard J; Barnett SW; Safrit JT; Stamatatos L Virology; 2004 Mar; 320(1):167-80. PubMed ID: 15003872 [TBL] [Abstract][Full Text] [Related]
32. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Tan GS; McKenna PM; Koser ML; McLinden R; Kim JH; McGettigan JP; Schnell MJ Virology; 2005 Jan; 331(1):82-93. PubMed ID: 15582655 [TBL] [Abstract][Full Text] [Related]
33. Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein. Zhan X; Slobod KS; Surman S; Brown SA; Lockey TD; Coleclough C; Doherty PC; Hurwitz JL J Virol; 2003 Apr; 77(7):4231-6. PubMed ID: 12634380 [TBL] [Abstract][Full Text] [Related]
34. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576 [No Abstract] [Full Text] [Related]
35. Clustering of Th cell epitopes on exposed regions of HIV envelope despite defects in antibody activity. Brown SA; Stambas J; Zhan X; Slobod KS; Coleclough C; Zirkel A; Surman S; White SW; Doherty PC; Hurwitz JL J Immunol; 2003 Oct; 171(8):4140-8. PubMed ID: 14530336 [TBL] [Abstract][Full Text] [Related]
36. B-cell antigenic sites in the envelope proteins of primate lentiviruses and their role in vaccine development. Norrby E; Matthews T AIDS; 1993; 7 Suppl 1():S127-33. PubMed ID: 8395859 [No Abstract] [Full Text] [Related]
37. Immunobiology of the human immunodeficiency virus envelope and its relationship to vaccine strategies. Bolognesi DP Mol Biol Med; 1990 Feb; 7(1):1-15. PubMed ID: 2182967 [TBL] [Abstract][Full Text] [Related]
38. Public health. AIDS vaccine still alive as booster after second failure in Thailand. Cohen J Science; 2003 Nov; 302(5649):1309-10. PubMed ID: 14631004 [No Abstract] [Full Text] [Related]
39. Peptide component vaccine engineering: targeting the AIDS virus. Cease KB Int Rev Immunol; 1990; 7(1):85-107. PubMed ID: 1722499 [TBL] [Abstract][Full Text] [Related]
40. HIV type 1-specific helper T cells: a critical host defense. Rosenberg ES; Walker BD AIDS Res Hum Retroviruses; 1998 Jun; 14 Suppl 2():S143-7. PubMed ID: 9672231 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]